SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

SANES

10.86

+2.28%↑

BBVA

19.72

+0.64%↑

BNP

94.42

+1.06%↑

CABK

11.555

+0.65%↑

INGA

26.375

+0.53%↑

Начало・Списък с акции・Bayer AG

Bayer AG

Отворен

СекторФинансови

36.08 2.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

35.02

Максимум

35.93

Ключови измерители
By Trading Economics
Приходи	6.5B 2.8B
Продажби	2B 13B
EPS	2.812
Дивидентна доходност	0.3
Марж на печалбата	20.612
Служители	87,757
EBITDA	2.3B 4.4B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+42.8% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.30% 4.65%
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.9B 35B
Предишно отваряне	33.2
Предишно затваряне	36.08

Настроения в новините

By Acuity

29%

71%

57 / 439 Класиране в Finance

Bayer AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 11:21 ч. UTC

Значими двигатели на пазара

Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement

12.05.2026 г., 11:24 ч. UTC

Печалби

Значими двигатели на пазара

Bayer Shares Climb After Earnings Beat Expectations

12.05.2026 г., 06:10 ч. UTC

Печалби

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6.05.2026 г., 10:51 ч. UTC

Придобивния, сливания и поглъщания

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6.05.2026 г., 07:01 ч. UTC

Придобивния, сливания и поглъщания

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2.06.2026 г., 11:22 ч. UTC

Пазарно говорене

Bayer Hit by New Roundup Legal Jitters -- Market Talk

29.05.2026 г., 08:15 ч. UTC

Пазарно говорене

Печалби

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

29.05.2026 г., 07:42 ч. UTC

Пазарно говорене

Bayer Can Still Take Hit if Litigation Strategy Fails -- Market Talk

12.05.2026 г., 12:05 ч. UTC

Горещи акции

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12.05.2026 г., 10:51 ч. UTC

Горещи акции

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12.05.2026 г., 09:08 ч. UTC

Горещи акции

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12.05.2026 г., 05:38 ч. UTC

Печалби

Bayer Backs 2026 Outlook Adjusted for Currency

12.05.2026 г., 05:36 ч. UTC

Печалби

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12.05.2026 г., 05:36 ч. UTC

Печалби

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12.05.2026 г., 05:36 ч. UTC

Печалби

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12.05.2026 г., 05:35 ч. UTC

Печалби

Bayer 1Q Adj EPS EUR2.71

12.05.2026 г., 05:34 ч. UTC

Печалби

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12.05.2026 г., 05:34 ч. UTC

Печалби

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12.05.2026 г., 05:34 ч. UTC

Печалби

Analysts Saw Bayer 1Q Sales at EUR13.42B

12.05.2026 г., 05:34 ч. UTC

Печалби

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12.05.2026 г., 05:33 ч. UTC

Печалби

Bayer 1Q EBIT EUR3.53B

12.05.2026 г., 05:32 ч. UTC

Печалби

Bayer 1Q Ebitda Before Special Items EUR4.45B

12.05.2026 г., 05:32 ч. UTC

Печалби

Bayer 1Q Net Pft EUR2.76B

12.05.2026 г., 05:31 ч. UTC

Печалби

Bayer 1Q Sales EUR13.405B

12.05.2026 г., 05:31 ч. UTC

Печалби

Bayer Backs 2026 View

6.05.2026 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6.05.2026 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6.05.2026 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6.05.2026 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

Bayer to Pay $300M Upfront

6.05.2026 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

Сравнение с други в отрасъла

Ценова промяна

Bayer AG Прогноза

Ценова цел

By TipRanks

42.8% нагоре

12-месечна прогноза

Среден 49.55 EUR 42.8%

Висок 56 EUR

Нисък 40 EUR

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Bayer AG през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Bayer AG през последните 3 месеца.

Настроение

By Acuity

57 / 439 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.